Silverback Therapeutics, Inc. (NASDAQ:SBTX – Get Free Report)’s share price traded up 3.3% on Friday. The company traded as high as $4.3550 and last traded at $4.32. Approximately 1,787,746 shares were traded during trading, an increase of 429% from the average daily volume of 337,931 shares. The stock had previously closed at $4.18.
Silverback Therapeutics Trading Up 3.3%
The firm has a market cap of $155.77 million, a price-to-earnings ratio of -1.79 and a beta of 0.60. The company’s 50-day moving average is $4.84 and its 200-day moving average is $6.86.
Silverback Therapeutics Company Profile
Silverback Therapeutics, Inc was a clinical-stage biopharmaceutical company focused on developing targeted medicines for cancer and other serious diseases. The company’s research centered on its ImmunoTAC platform, which was designed to use antibody-based targeting to deliver immune-modulating payloads to specific tissues and disease sites.
Silverback developed a pipeline of investigational programs intended to address conditions involving the immune system, including oncology and fibrotic diseases.
Further Reading
- Five stocks we like better than Silverback Therapeutics
- Spotify Soars After Earnings as the Company Touts AI Benefits and Moderating Costs
- Lockheed Martin’s Record $292 Billion Backlog Comes With a Delivery Test
- Palantir’s Next Big Test Isn’t a Partnership—It’s the Numbers
- Kinder Morgan’s $4.7 Billion Pipeline Bet Could Be Bigger Than Its Earnings Beat
Receive News & Ratings for Silverback Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Silverback Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
-logo-1200x675.png){kind=logo}